<DOC>
	<DOCNO>NCT00424697</DOCNO>
	<brief_summary>Data suggest imaging activity brain measure effect anti-anxiety drug . This study investigate effect GW876008 area brain involve thinking emotion</brief_summary>
	<brief_title>A Study Investigate Effects GW876008 Brain Activation During Emotional Processing Healthy Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Lorazepam</mesh_term>
	<criteria>Healthy male female age 1850 year , inclusive . STAItrait score = &gt; 40 . STAIstate score &lt; 50th percentile normal population distribution . Female subject nonchildbearing . Female subject childbearing potential must agree use appropriate contraception . Healthy subject , determine responsible physician Body weight â‰¥ 50 kg ( 110 lb ) , BMI within range 1929.9 kg/m2 inclusive . Demonstrates significant evidence active disease , physical mental impairment assess qualified personnel Nonsmoker ( abstinence smoking least 6 month start study ) . Normal electrocardiogram . Capable give write informed consent , include compliance requirement restriction list consent form . Read , comprehend , write English sufficient level complete studyrelated material . Provide sign date write informed consent prior study participation As result medical interview , physical examination , evaluation mental state psychiatric history screen investigation physician responsible considers subject unfit study . Any history suicidal attempt behaviour . Any history current diagnosis psychiatric illness . Any history endocrine disorder include , limited , diabetes disorder hypothalamus , pituitary , adrenal , thyroid gland , gonadal disorder dysfunction reproductive organ . Abnormal pepsinogen I level screen . Liver Function Tests ( LFTs ) elevate reference range prestudy screen remain elevated repeat LFT Any clinically significant laboratory abnormality . Positive faecal occult blood test . Positive prestudy urine drug/alcohol breath screen . Positive prestudy HIV 1/2 , Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month start study . Preexisting current Helicobactor pylorus infection . History alcohol/drug abuse dependence within 12 month study Consumption grapefruit juice grapefruit within 14 day prior first dose study medication . History peptic ulcer disease . Abnormal screen ECG History long QT syndrome ( personal family ) cardiac conduction disorder , clinically significant cardiac disease . Systolic blood pressure &lt; 90mmHg &gt; 140mmHg ; diastolic blood pressure &lt; 60mmHg &gt; 90mmHg ; pulse rate &lt; 40bpm &gt; 90bpm . Participation clinical trial drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication . History sensitivity study medication , component thereof history drug allergy , opinion physician responsible , contraindicate participation . History current diagnosis acute narrow angle glaucoma . Where participation study would result donation blood excess 500 mL within 56 day period . Current recent ( within one year ) gastrointestinal disease ; history malabsorption , esophageal reflux , irritable bowel syndrome ; frequent ( week ) occurrence heartburn ; surgical intervention ( e.g. , cholecystectomy ) would expect influence absorption drug . Average daily caffeine intake equivalent &gt; 4 cup coffee &gt; 6 cup tea . Subjects leave hand .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Brain imaging ,</keyword>
	<keyword>fMRI ,</keyword>
	<keyword>stimulation ,</keyword>
	<keyword>pharmacodynamics ,</keyword>
	<keyword>tolerability ,</keyword>
	<keyword>healthy subject</keyword>
</DOC>